Ronald Herbst

11.5k total citations · 2 hit papers
130 papers, 6.5k citations indexed

About

Ronald Herbst is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Ronald Herbst has authored 130 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Immunology, 47 papers in Oncology and 40 papers in Molecular Biology. Recurrent topics in Ronald Herbst's work include Immune Cell Function and Interaction (26 papers), T-cell and B-cell Immunology (23 papers) and Monoclonal and Polyclonal Antibodies Research (22 papers). Ronald Herbst is often cited by papers focused on Immune Cell Function and Interaction (26 papers), T-cell and B-cell Immunology (23 papers) and Monoclonal and Polyclonal Antibodies Research (22 papers). Ronald Herbst collaborates with scholars based in United States, Germany and United Kingdom. Ronald Herbst's co-authors include Anthony J. Coyle, Gary P. Sims, Daniel C. Rowe, Svend T. Rietdijk, Rachel Ettinger, A. Ullrich, Michael A. Simon, John Allard, Daniela Bruni and Helen K. Angell and has published in prestigious journals such as Cell, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Ronald Herbst

129 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

HMGB1 and RAGE in Inflammation and Cancer

2010 1.2k citations Gary P. Sims, Ronald Herbst et al. profile →
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

2018 449 citations Elaine M. Hurt, Ronald Herbst et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ronald Herbst United States	39	2.8k	2.4k	2.0k	925	647	130	6.5k
Vincent Castronovo Belgium	49	1.6k 0.6×	4.2k 1.8×	1.6k 0.8×	489 0.5×	318 0.5×	117	6.7k
Jochen Heß Germany	36	1.4k 0.5×	3.2k 1.4×	1.4k 0.7×	601 0.6×	316 0.5×	125	5.8k
David H. Lovett United States	50	1.0k 0.4×	2.5k 1.0×	995 0.5×	563 0.6×	374 0.6×	126	6.6k
Takahiro Kodama Japan	39	1.3k 0.5×	2.4k 1.0×	824 0.4×	461 0.5×	415 0.6×	176	5.8k
Katherine A. Siminovitch Canada	52	4.2k 1.5×	3.6k 1.5×	1.2k 0.6×	202 0.2×	333 0.5×	136	8.8k
Thomas Longerich Germany	45	999 0.4×	3.3k 1.4×	1.4k 0.7×	706 0.8×	495 0.8×	205	7.4k
Masamichi Goto Japan	35	626 0.2×	1.6k 0.7×	1.2k 0.6×	398 0.4×	252 0.4×	114	3.5k
Peter J. Gough United States	45	4.4k 1.6×	6.0k 2.5×	1.5k 0.7×	849 0.9×	207 0.3×	80	9.6k
Masakiyo Sakaguchi Japan	41	925 0.3×	3.2k 1.3×	737 0.4×	652 0.7×	175 0.3×	195	5.5k
Manuel O. Landázuri Spain	47	2.8k 1.0×	2.7k 1.2×	900 0.4×	366 0.4×	199 0.3×	109	6.9k

Countries citing papers authored by Ronald Herbst

Since Specialization

Citations

This map shows the geographic impact of Ronald Herbst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald Herbst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald Herbst more than expected).

Fields of papers citing papers by Ronald Herbst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald Herbst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald Herbst. The network helps show where Ronald Herbst may publish in the future.

Co-authorship network of co-authors of Ronald Herbst

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald Herbst. A scholar is included among the top collaborators of Ronald Herbst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald Herbst. Ronald Herbst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ramaswamy, Madhu, Tae Il Kim, Des C. Jones, et al.. (2021). Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1. Cancer Immunology Research. 10(2). 200–214. 16 indexed citations

Dalby, Elizabeth, Stephen M. Christensen, Jingya Wang, et al.. (2020). Immune Complex–Driven Generation of Human Macrophages with Anti-Inflammatory and Growth-Promoting Activity. The Journal of Immunology. 205(1). 102–112. 10 indexed citations

Mansuet‐Lupo, Audrey, Marc Barritault, Marco Alifano, et al.. (2019). Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors. Journal of Thoracic Oncology. 14(5). 844–856. 59 indexed citations

Biton, Jérôme, Audrey Mansuet‐Lupo, Nicolas Pécuchet, et al.. (2018). TP53, STK11 , and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma. Clinical Cancer Research. 24(22). 5710–5723. 251 indexed citations

Zhong, Haihong, Chen Cui, Ravinder Tammali, et al.. (2018). Improved Therapeutic Window in BRCA -mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition. Molecular Cancer Therapeutics. 18(1). 89–99. 12 indexed citations

Kinneer, Krista, John Meekin, Arnaud Tiberghien, et al.. (2018). SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads. Clinical Cancer Research. 24(24). 6570–6582. 58 indexed citations

Pore, Nabendu, Kevin Schifferli, Noel R. Monks, et al.. (2018). Discovery and Development of MEDI7247, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2, for Treating Hematological Cancers. Blood. 132(Supplement 1). 4071–4071. 7 indexed citations

Xiao, Zhan, Rosa A. Carrasco, Kevin Schifferli, et al.. (2016). A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response. Molecular Cancer Therapeutics. 15(4). 689–701. 27 indexed citations

Ding, Chen, Sara Ireland, Laurie S. Davis, et al.. (2016). Autoreactive CD19+CD20− Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis. The Journal of Immunology. 196(4). 1541–1549. 36 indexed citations

10.

Schiopu, Elena, Soumya Chatterjee, Vivien Hsu, et al.. (2016). Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Research & Therapy. 18(1). 131–131. 60 indexed citations

11.

Seys, Leen, Anne Verhamme, Anja Schuster, et al.. (2015). Role of B Cell–Activating Factor in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 192(6). 706–718. 84 indexed citations

12.

Bracke, Ken R., Anne Verhamme, Leen Seys, et al.. (2013). Role of CXCL13 in Cigarette Smoke–induced Lymphoid Follicle Formation and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 188(3). 343–355. 80 indexed citations

13.

Gallagher, Sandra, Yue Wang, Chris Groves, et al.. (2009). Macrophages are required for anti-CD19 mAb mediated B cell depletion in mice (50.16). The Journal of Immunology. 182(Supplement_1). 50.16–50.16. 2 indexed citations

14.

Vijapurkar, Ulka, Wei Wang, & Ronald Herbst. (2007). Potentiation of Kinesin Spindle Protein Inhibitor–Induced Cell Death by Modulation of Mitochondrial and Death Receptor Apoptotic Pathways. Cancer Research. 67(1). 237–245. 30 indexed citations

15.

Chin, Gregory M. & Ronald Herbst. (2006). Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint. Molecular Cancer Therapeutics. 5(10). 2580–2591. 39 indexed citations

16.

Pettiford, S M & Ronald Herbst. (2003). The protein tyrosine phosphatase HePTP regulates nuclear translocation of ERK2 and can modulate megakaryocytic differentiation of K562 cells. Leukemia. 17(2). 366–378. 27 indexed citations

17.

Pogue, Sarah, Tomohiro Kurosaki, Joseph B. Bolen, & Ronald Herbst. (2000). B Cell Antigen Receptor-Induced Activation of Akt Promotes B Cell Survival and Is Dependent on Syk Kinase. The Journal of Immunology. 165(3). 1300–1306. 121 indexed citations

18.

Kubota, Yoshiyuki, et al.. (1998). Activation of phosphatidylinositol 3-kinase is necessary for differentiation of FDC-P1 cells following stimulation of type III receptor tyrosine kinases.. PubMed. 9(3). 247–56. 25 indexed citations

19.

Allard, John, Ronald Herbst, Pamela M. Carroll, & Michael A. Simon. (1998). Mutational Analysis of the SRC Homology 2 Domain Protein-tyrosine Phosphatase Corkscrew. Journal of Biological Chemistry. 273(21). 13129–13135. 22 indexed citations

20.

Bühring, Hans‐Jörg, Ronald Herbst, Birgit Bossenmaier, et al.. (1993). Modulation of p145c-kit function in cells of patients with acute myeloblastic leukemia.. PubMed. 53(18). 4424–31. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact